DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ffr7vc/male_infertility) has announced the addition of the "Male Infertility - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Male Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Infertility and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AlphaMab Co., Ltd
- Pantarhei Bioscience BV
- PharmaEssentia Corporation
- PlasmaTech Biopharmaceuticals, Inc.
- Zydus Cadila Healthcare Limited
- (oxytocin + estrogen)
- Biosimilar 4 for Acute Myocardial Infarction and Infertility
- Biosimilar 5 for Infertility
- Biosimilar 6 for Infertility
- Biosimilar 7 for Infertility and Oncology
- Oral Fertility Drugs
- Small Molecule to Agonize FSHR for Infertility
- Small Molecules for Male Infertility
- Stem Cell Therapy for Male Infertility
For more information visit http://www.researchandmarkets.com/research/ffr7vc/male_infertility